Asset Details
Do you wish to reserve the book?
Evaluation of core Biomarkers of Alzheimer’s disease in saliva and plasma measured by chemiluminescent enzyme immunoassays on a fully automated platform
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Evaluation of core Biomarkers of Alzheimer’s disease in saliva and plasma measured by chemiluminescent enzyme immunoassays on a fully automated platform
Do you wish to request the book?
Evaluation of core Biomarkers of Alzheimer’s disease in saliva and plasma measured by chemiluminescent enzyme immunoassays on a fully automated platform
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Evaluation of core Biomarkers of Alzheimer’s disease in saliva and plasma measured by chemiluminescent enzyme immunoassays on a fully automated platform
2024
Overview
Cerebrospinal fluid (CSF) core biomarkers of Alzheimer’s disease (AD), including amyloid peptide beta-42 (Aβ42), Aβ42/40 ratio, and phosphorylated tau (pTau), are precious tools for supporting AD diagnosis. However, their use in clinical practice is limited due to the invasiveness of CSF collection. Thus, there is intensive research to find alternative, noninvasive, and widely accessible biological matrices to measure AD
core
biomarkers. In this study, we measured AD
core
biomarkers in saliva and plasma by a fully automated platform. We enrolled all consecutive patients with cognitive decline. For each patient, we measured Aβ42, Aβ40, and pTau levels in CSF, saliva, and plasma by Lumipulse G1200 (Fujirebio). We included forty-two patients, of whom 27 had AD. Levels of all biomarkers significantly differed in the three biofluids, with saliva having the lowest and CSF the highest levels of Aβ42, Aβ40, and pTau. A positive correlation of pTau, Aβ42/40 ratio, and pTau/Aβ42 ratio levels in CSF and plasma was detected, while no correlation between any biomarker in CSF and saliva was found. Our findings suggest that plasma but not saliva could represent a surrogate biofluid for measuring
core
AD biomarkers. Specifically, plasma Aβ42/40 ratio, pTau/Aβ42 ratio, and pTau could serve as surrogates of the corresponding CSF biomarkers.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ 692/53
/ 692/617
/ 692/699
/ Aged
/ Alzheimer Disease - cerebrospinal fluid
/ Alzheimer Disease - diagnosis
/ Alzheimer Disease - metabolism
/ Amyloid beta-Peptides - analysis
/ Amyloid beta-Peptides - blood
/ Amyloid beta-Peptides - cerebrospinal fluid
/ Biomarkers - cerebrospinal fluid
/ Female
/ Humanities and Social Sciences
/ Humans
/ Luminescent Measurements - methods
/ Male
/ Peptide Fragments - analysis
/ Peptide Fragments - cerebrospinal fluid
/ Plasma
/ Saliva
/ Science
/ Tau
